A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a CYP3 inhibitor
1403-0004
Phase 1 other active
Quick answer
A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a CYP3 inhibitor for Solid cancer tumors is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- Solid cancer tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active